2011 Fiscal Year Final Research Report
Development of cancer immunotherapy using co-transfer of cancer-specific TCR gene and chemokine receptor gene
| Project/Area Number |
21390294
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
YASUKAWA Masaki 愛媛大学, 大学院・医学系研究科, 教授 (60127917)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HASEGAWA Hitoshi 愛媛大学, 大学院・医学系研究科, 准教授 (40164826)
FUJIWARA Hiroshi 愛媛大学, 医学部附属病院, 講師 (20398291)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | がん免疫療法 / T細胞レセプター遺伝子 / ケモカイン・ケモカインレセプター / WT1 / Aurora-A kinase / 白血病 / 肺がん |
|---|
| Research Abstract |
In order to develop a novel cancer immunotherapy, we verified the efficacy and safety of adoptive transfer using cytotoxic T lymphocytes(CTLs) transduced with cancer-specific T-cell receptor(TCR) gene and receptor gene for chemokine which is abundantly produced in cancer microenvironment. Our data demonstrate that adoptive transfer of artificial CTLs expressing both cancer-specific TCR and chemokine receptor is more effective and safe than that of CTLs expressing only cancer-specific TCR.
|
